<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01110941</url>
  </required_header>
  <id_info>
    <org_study_id>SOL feasibility study</org_study_id>
    <nct_id>NCT01110941</nct_id>
  </id_info>
  <brief_title>Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) for Colorectal Cancer in China</brief_title>
  <acronym>SCI-101</acronym>
  <official_title>A Multicenter Feasibility Study With S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients With Untreated Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shen Lin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>307 Hospital of PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Union Hosptial</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Provincial Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <brief_summary>
    <textblock>
      S-1 is an oral fluoropyrimidine with demonstrated efficacy on gastric cancer and colorectal&#xD;
      cancer. The new regimen with Oxaliplatin and leucovorin is expected to achieve more&#xD;
      encouraging efficacy on colorectal cancer. This study is to explore the feasibility of the&#xD;
      SOL regimen on efficacy and tolerability on Chinese colorectal cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Endpoints:&#xD;
&#xD;
        -  Primary endpoints: adverse drug reaction&#xD;
&#xD;
        -  Secondary endpoints:&#xD;
&#xD;
             -  Overall Response Rate：ORR&#xD;
&#xD;
             -  Progress Free Survival: PFS&#xD;
&#xD;
             -  Time to Treatment Failure：TTF&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>from first administration till 28 days after last dosage</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, and follow up till disease progression or withdrawal from study due to intolerable adverse events (AE)</measure>
    <time_frame>every 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>SOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1, leucovorin, oxaliplatin</intervention_name>
    <description>S-1(20mg、25mg), capsule, 40~60mg, Bid,p.o., day1~7； LV (25 mg), tablet, 25mg,Bid,p.o., day1~7； L-OHP (50 mg),injection 85mg/m2, day1. repeated at every 2 weeks cycle till disease progression.</description>
    <arm_group_label>SOL</arm_group_label>
    <other_name>S-1(20mg、25mg)--Taiho Pharmaceutical Co., Ltd.；</other_name>
    <other_name>LV (25 mg)；</other_name>
    <other_name>L-OHP (50 mg)--Sanofi Aventis Co., Ltd.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Advanced unresectable or recurrent colorectal cancer patients which meet the following&#xD;
             criteria:&#xD;
&#xD;
               -  Willing to sign ICF&#xD;
&#xD;
               -  Could orally take investigational product&#xD;
&#xD;
               -  Pathology diagnosis is adenocarcinoma&#xD;
&#xD;
               -  Above 20 years&#xD;
&#xD;
               -  No previous treatment(including: radiotherapy,chemotherapy and immunotherapy)&#xD;
&#xD;
               -  For recurrent cases, if the patient had received adjuvant chemotherapy that&#xD;
                  didn't include S-1 and L-OHP in 180 days ago, he/she could be enrolled in&#xD;
&#xD;
               -  With target lesions with diameter which is longer than 1cm in spiral CT or MRI&#xD;
                  examination within 30 days&#xD;
&#xD;
          -  Lab test within 15 days meet following criteria&#xD;
&#xD;
               -  Hemoglobin higher than 9.0g/dL&#xD;
&#xD;
               -  Leukocyte higher than 12,000/mm3&#xD;
&#xD;
               -  Neutrophil higher than 2,000/mm3&#xD;
&#xD;
               -  PLT higher than 10.0 104/mm3&#xD;
&#xD;
               -  Bilirubin lower than 1.5 times of upper limit of normal range&#xD;
&#xD;
               -  AST,ALT,ALP lower than 2.5 times of upper limit of normal range&#xD;
&#xD;
               -  Creatinine lower than upper limit of normal range&#xD;
&#xD;
        When patient has liver metastasis or bone metastasis, the value of AST,ALT,ALP could be&#xD;
        within 5 times of upper limit of normal range&#xD;
&#xD;
          -  ECOG 0 or 1&#xD;
&#xD;
          -  Expected survival time more than 90 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient who meet the following criteria should be excluded from this trial&#xD;
&#xD;
          -  Patients who have severe drug allergic history(including: platinum related&#xD;
             drugs,5-FU,FT,LV,5-HT3 receptor antagonist)&#xD;
&#xD;
          -  Attended other clinical trial within 4 weeks&#xD;
&#xD;
          -  Received transfusion of blood,related products or G-CSF within 15 days&#xD;
&#xD;
          -  Received surgery within 4 weeks and the effect hadn't vanished&#xD;
&#xD;
          -  Have diarrhea&#xD;
&#xD;
          -  Have complication of active infection(infection caused fever higher than 38℃)&#xD;
&#xD;
          -  Have complication of poor controlled hypercalcemia,hypertension,diabetes&#xD;
&#xD;
          -  Have complication of severe ECG abnormal or other heart disease which will affect&#xD;
             clinical treatment(including: cardiac dysfunction,myocardial infarction,angina)&#xD;
&#xD;
          -  Have complication of severe pulmonary disease(including:interstitial&#xD;
             pneumonia,pulmonary fibrosis,severe emphysema)&#xD;
&#xD;
          -  Have complication of psychiatric disorder which will affect clinical treatment or have&#xD;
             history of CNS disease&#xD;
&#xD;
          -  Have complication of active gastrointestinal bleeding&#xD;
&#xD;
          -  Have pleural effusion,ascites or pericardial effusion that need drainage&#xD;
&#xD;
          -  Have complication of multiple bone metastasis&#xD;
&#xD;
          -  Have severe complication(including:ileus,renal insufficiency,hepatic&#xD;
             insufficiency,cerebrovascular disturbance)&#xD;
&#xD;
          -  Have brain metastasis or suspicious brain metastasis&#xD;
&#xD;
          -  Have active multiple primary cancer&#xD;
&#xD;
          -  Female patients who are in pregnancy or lactation and patients who are not willing to&#xD;
             take contraception measures&#xD;
&#xD;
          -  Investigator judge not eligible to this trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>April 21, 2010</study_first_submitted>
  <study_first_submitted_qc>April 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2010</study_first_posted>
  <last_update_submitted>May 17, 2015</last_update_submitted>
  <last_update_submitted_qc>May 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>pro</investigator_title>
  </responsible_party>
  <keyword>S-1</keyword>
  <keyword>leucovorin</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>SOL</keyword>
  <keyword>unresectable or recurrent colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

